Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035362) USE OF COMPLEMENT PATHWAY INHIBITOR COMPOUNDS TO MITIGATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE IMMUNE RESPONSES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/035362 International Application No.: PCT/US2016/048710
Publication Date: 02.03.2017 International Filing Date: 25.08.2016
IPC:
A61K 39/395 (2006.01) ,C07K 16/30 (2006.01) ,A61K 31/4025 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025
not condensed and containing further heterocyclic rings, e.g. cromakalim
Applicants:
ACHILLION PHARMACEUTICALS, INC. [US/US]; 300 George Street New Haven, CT 06511, US
Inventors:
HUANG, Mingjun; US
FISHERMAN, Jason; US
Agent:
BELLOWS, Brent, R.; US
KNOWLES, Sherry, M; US
Priority Data:
62/210,41526.08.2015US
Title (EN) USE OF COMPLEMENT PATHWAY INHIBITOR COMPOUNDS TO MITIGATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE IMMUNE RESPONSES
(FR) UTILISATION DE COMPOSÉS INHIBITEURS DE LA VOIE DU COMPLÉMENT POUR ATTÉNUER DES RÉPONSES IMMUNITAIRES INDÉSIRABLES ASSOCIÉES À UNE THÉRAPIE ADOPTIVE PAR LYMPHOCYTES T
Abstract:
(EN) This invention provides methods for treating adoptive T-cell therapy-associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using complement pathway inhibitor compounds.
(FR) L'invention concerne des procédés pour traiter des réponses inflammatoires indésirables associées à une thérapie adoptive par lymphocytes T, telles que le syndrome de libération de cytokines et le syndrome de lyse tumorale, à l'aide de composés inhibiteurs de la voie du complément.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)